Table 1. Clinical and pathological characteristics of study participants.
| Characteristics | No. (%) | P (Cox univariate and multivariate analysis for overall survival) |
|---|---|---|
| Total No. patients | 59 (100%) | |
| MTHFR C677T | 0.777 and 0.849 | |
| CC | 15 (25.4%) | |
| CT | 20 (33.9%) | |
| TT | 24 (40.7%) | |
| MTHFR A1298C | ||
| AA | 58 (98.3%) | |
| AC | 1 (1.7%) | |
| CC | 0 (0.0%) | |
| Age at diagnosis, y | 0.416 and 0.909 | |
| Median (range) | 16.0 (5–52) | |
| Follow-up, mo | ||
| Median (range) | 39.1 (29.4–69.6) | |
| Gender | 0.866 and 0.475 | |
| Male | 37 (62.7%) | |
| Female | 22 (37.3%) | |
| Primary location | 0.089 and 0.056 | |
| axial skeleton | 12 (20.3%) | |
| distal femur | 24 (40.7%) | |
| proximal tibia | 12 (20.3%) | |
| proximal humerus | 8 (13.6%) | |
| proximal femur | 1 (1.7%) | |
| distal tibia and fibula | 2 (3.4%) | |
| Metastasis at diagnosis | 0.004 and 0.033 | |
| Absent | 39 (66.1%) | |
| Present | 20 (33.9%) | |
| Histological subtype | 0.059 and 0.052 | |
| Common type(osteoblastic, chondroblastic, fibroblastic) | 36 (61.0%) | |
| Telangiectatic type | 3 (5.1%) | |
| Histological response | 0.164 and 0.294 | |
| Good (≥90%) | 11 (18.6%) | |
| Poor (<90%) | 33 (55.9%) | |
| Not evaluable | 15 (25.4%) | |
| Death | ||
| Yes | 28 (47.5%) | |
| No | 31 (52.5%) | |
| Progression | ||
| Yes | 36 (61.0%) | |
| No | 23 (39.0%) |
Only one patient was tested as heterozygous mutant genotype of A1298C with a mutation frequency of 0.84%, thus no statistical calculation has been done due to its low incidence. As for the incidence of C667T, 15 (25.4%) patients had wild type, 20 (33.9%) had heterozygous mutant genotype and 24 (40.7%) had homozygous mutant genotype with the genic mutation frequency of 57.7%.